{"nctId":"NCT04432376","briefTitle":"Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis)","startDateStruct":{"date":"2020-07-08","type":"ACTUAL"},"conditions":["Otomycosis"],"count":382,"armGroups":[{"label":"Active treatment arm","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: miconazole 2% oil"]},{"label":"Placebo treatment arm","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: vehicle oil"]},{"label":"Open-label treatment arm","type":"OTHER","interventionNames":["Drug: miconazole 2% oil"]}],"interventions":[{"name":"miconazole 2% oil","otherNames":["active treatment"]},{"name":"vehicle oil","otherNames":["placebo treatment"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nRandomized blinded initial phase of study:\n\n* Male or non-pregnant, non-lactating females with a clinical diagnosis of uncomplicated otomycosis of the external ear only,\n* Intact tympanic membrane in the ear(s) to be treated with study drug,\n* In general good health as determined by medical examination and medical history,\n* Free of clinically significant disease, including diabetes mellitus, that is not well-controlled or that could interfere with the study.\n\nOpen-label second phase of study:\n\n* Male or non-pregnant, non-lactating females with an intact tympanic membrane in the ear(s) to be treated with study drug,\n* In general good health as determined by medical examination and medical history,\n* Free of clinically significant disease, including diabetes mellitus, that is not well-controlled or that could interfere with the study.\n\nExclusion Criteria::\n\n* Presence of dermatoses or conditions of the ear that may interfere with evaluation of otomycosis or with safety evaluations, including concomitant otic infections that require antimicrobial treatment,\n* Disease that has spread beyond the external ear(s), or pre-existing skin atrophy of the affected ear(s);\n* Tympanostomy tube or perforated tympanic membrane;\n* History of prior surgery directly affecting and compromising the external auditory canal and/or tympanic membrane, except for prior tympanostomy tube(s) that have already been removed and completely healed;\n* Use of any topical medicated treatments for otomycosis within 14 days of study entry;\n* Use of any systemic antifungal therapy within 28 days of study entry, warfarin within 28 days of study entry, immunosuppressive or immune-stimulating drugs within 28 days of study entry, or systemic steroids within 3 months of study entry;\n* Fever of ≥100°F at study entry;\n* Otomycosis that has been unresponsive to previous antifungal treatment;\n* Known hypersensitivity to any of the components in the test formulation;\n* Participation in another investigative trial within 28 days of study entry","healthyVolunteers":true,"sex":"ALL","minimumAge":"7 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With Therapeutic Cure","description":"\"therapeutic cure\" is \"mycological cure\" plus \"clinical cure, in the Modified intent to treat (MITT) only: patients with + fungal culture at baseline. Fungal culture results verified as (+) or (-) after enrollment.\n\nIntent to treat (ITT) population were all subjects enrolled and randomized. Active group: ITT=89 (100%), MITT=67 (75.3%); Placebo Group: ITT=90 (100%), MITT=64 (71.1%).\n\nMycological cure is a negative mycological culture (culture is either positive or negative). Score=0 is best.\n\nClinical cure is absence of all otomycosis signs and symptoms (s/s) of Pruritus, Debris, and Aural fullness, graded as (scores) 0=none, 1=mild, 2=moderate, 3=severe; and Presence of fungal elements, score 0=No fungal elements, 1=fungal elements present on visual inspection. Score=0 is best.\n\nEfficacy analysis was performed only on MITT (modified intent-to-treat) population, consisting of only those patients that had positive fungal culture at Baseline.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Mycological Cure","description":"Mycological cure is a negative mycological culture for the study ear at test of cure visit, in Modified intent to treat (MITT) only: patients with + fungal culture at baseline. Subjects that had negative fungal culture at Baseline were not included in MITT. Fungal culture results verified as (+) or (-) after enrollment.\n\nGrading is based on positive or negative mycological (fungal) culture. Negative culture is required.\n\nEfficacy analysis was performed only on MITT (modified intent-to-treat) population, consisting of only those patients that had positive fungal culture at Baseline.\n\nIntent to treat (ITT) population were all subjects enrolled and randomized. Active group: ITT=89 (100%), MITT=67 (75.3%); Placebo Group: ITT=90 (100%), MITT=64 (71.1%).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Clinical Cure","description":"Absence of all otomycosis signs and symptoms according to the scales for each individual sign/symptom. Score=0 is best.\n\nClinical cure is absence of all otomycosis signs and symptoms of Pruritus, Debris, and Aural fullness, graded as (scores) 0=none, 1=mild, 2=moderate, 3=severe; and Presence of fungal elements, score 0=No fungal elements, 1=fungal elements present on visual inspection. Score=0 is best.\n\nEfficacy analysis was performed only on MITT (modified intent-to-treat) population, consisting of only those patients that had positive fungal culture at Baseline. Subjects that had negative fungal culture at Baseline were not included in MITT. Fungal culture results verified as (+) or (-) after enrollment.\n\nITT (intent to treat) population were all subjects enrolled and randomized. Active group: ITT=89 (100%), MITT=67 (75.3%); Placebo Group: ITT=90 (100%), MITT=64 (71.1%).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"14","spread":null}]},{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":89},"commonTop":["ear infection fungal","application site pruritus","ear discomfort","application site pain","otitis externa"]}}}